AbbVie annual free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Free Cash Flow (FCF) History (ABBV)
AbbVie reported $17.82B in free cash flow for fiscal 2025, a decrease of 0.09% from the previous fiscal year, with a free cash flow margin of 29.13%.
View full AbbVie company overviewAbbVie free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.82B | −$16.0M | −0.09% | +29.13% |
| 2024 | 2024-12-31 | $17.83B | −$4.23B | −19.17% | +31.65% |
| 2023 | 2023-12-31 | $22.06B | −$2.19B | −9.02% | +40.62% |
| 2022 | 2022-12-31 | $24.25B | $2.26B | +10.27% | +41.77% |
| 2021 | 2021-12-31 | $21.99B | $5.20B | +30.97% | +39.13% |
| 2020 | 2020-12-31 | $16.79B | $4.02B | +31.46% | +36.66% |
| 2019 | 2019-12-31 | $12.77B | −$17.0M | −0.13% | +38.39% |
| 2018 | 2018-12-31 | $12.79B | $3.36B | +35.61% | +39.05% |
| 2017 | 2017-12-31 | $9.43B | $2.87B | +43.72% | +33.42% |
| 2016 | 2016-12-31 | $6.56B | −$441.0M | −6.30% | +25.59% |
| 2015 | 2015-12-31 | $7.00B | $4.07B | +138.44% | +30.64% |
| 2014 | 2014-12-31 | $2.94B | −$2.84B | −49.15% | +14.71% |
| 2013 | 2013-12-31 | $5.78B | −$236.0M | −3.93% | +30.74% |
| 2012 | 2012-12-31 | $6.01B | $121.0M | +2.05% | +32.71% |
| 2011 | 2011-12-31 | $5.89B | — | — | +33.77% |
AbbVie quarterly free cash flow
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.11B | −$1.77B | −36.24% | +18.33% |
| Q1 2026 | 2026-03-31 | $3.56B | $2.16B | +154.57% | +23.76% |
| Q4 2025 | 2025-12-31 | $4.89B | −$1.87B | −27.65% | +29.42% |
| Q3 2025 | 2025-09-30 | $6.64B | $1.45B | +27.80% | +42.11% |
| Q2 2025 | 2025-06-30 | $4.88B | $2.85B | +140.59% | +31.67% |
| Q1 2025 | 2025-03-31 | $1.40B | −$2.45B | −63.61% | +10.49% |
| Q4 2024 | 2024-12-31 | $6.76B | — | — | +44.74% |
| Q3 2024 | 2024-09-30 | $5.20B | −$2.16B | −29.33% | +35.95% |
| Q2 2024 | 2024-06-30 | $2.03B | −$4.11B | −66.94% | +14.04% |
| Q1 2024 | 2024-03-31 | $3.85B | −$171.0M | −4.26% | +31.25% |
| Q3 2023 · Sep 30 | 2023-09-30 | $7.36B | −$70.0M | −0.94% | +52.81% |
| Q2 2023 · Jun 30 | 2023-06-30 | $6.14B | $1.28B | +26.31% | +44.29% |
| Q1 2023 · Mar 31 | 2023-03-31 | $4.02B | −$728.0M | −15.34% | +32.87% |
| Q3 2022 · Sep 30 | 2022-09-30 | $7.42B | −$293.0M | −3.80% | +50.13% |
| Q2 2022 · Jun 30 | 2022-06-30 | $4.86B | $167.0M | +3.56% | +33.34% |
| Q1 2022 · Mar 31 | 2022-03-31 | $4.75B | $57.0M | +1.22% | +35.06% |
| Q3 2021 · Sep 30 | 2021-09-30 | $7.72B | $2.10B | +37.50% | +53.81% |
| Q2 2021 · Jun 30 | 2021-06-30 | $4.70B | $1.78B | +61.23% | +33.63% |
| Q1 2021 · Mar 31 | 2021-03-31 | $4.69B | $999.0M | +27.07% | +36.04% |
| Q3 2020 · Sep 30 | 2020-09-30 | $5.61B | $1.21B | +27.54% | +43.50% |
| Q2 2020 · Jun 30 | 2020-06-30 | $2.91B | $563.0M | +23.97% | +27.93% |
| Q1 2020 · Mar 31 | 2020-03-31 | $3.69B | $780.0M | +26.80% | +42.81% |
| Q3 2019 · Sep 30 | 2019-09-30 | $4.40B | $159.0M | +3.75% | +51.90% |
| Q2 2019 · Jun 30 | 2019-06-30 | $2.35B | −$403.0M | −14.64% | +28.46% |
| Q1 2019 · Mar 31 | 2019-03-31 | $2.91B | $384.0M | +15.20% | +37.17% |
| Q3 2018 · Sep 30 | 2018-09-30 | $4.24B | $1.10B | +34.88% | +51.51% |
| Q2 2018 · Jun 30 | 2018-06-30 | $2.75B | $875.0M | +46.62% | +33.24% |
| Q1 2018 · Mar 31 | 2018-03-31 | $2.53B | $519.0M | +25.86% | +31.84% |
| Q3 2017 · Sep 30 | 2017-09-30 | $3.15B | $1.80B | +134.53% | +44.96% |
| Q2 2017 · Jun 30 | 2017-06-30 | $1.88B | $90.0M | +5.04% | +27.03% |
| Q1 2017 · Mar 31 | 2017-03-31 | $2.01B | $0 | 0.00% | +30.70% |
| Q3 2016 · Sep 30 | 2016-09-30 | $1.34B | −$687.0M | −33.88% | +20.85% |
| Q2 2016 · Jun 30 | 2016-06-30 | $1.79B | $70.0M | +4.08% | +27.70% |
| Q1 2016 · Mar 31 | 2016-03-31 | $2.01B | $567.0M | +39.38% | +33.69% |
| Q3 2015 · Sep 30 | 2015-09-30 | $2.03B | $422.0M | +26.28% | +34.12% |
| Q2 2015 · Jun 30 | 2015-06-30 | $1.72B | $142.0M | +9.02% | +31.36% |
| Q1 2015 · Mar 31 | 2015-03-31 | $1.44B | $953.0M | +195.69% | +28.57% |
| Q4 2014 | 2014-12-31 | −$731.0M | −$1.82B | — | −13.41% |
| Q3 2014 | 2014-09-30 | $1.61B | −$59.0M | −3.54% | +32.00% |
| Q2 2014 | 2014-06-30 | $1.57B | −$343.0M | −17.88% | +31.97% |
| Q1 2014 | 2014-03-31 | $487.0M | −$612.0M | −55.69% | +10.67% |
| Q4 2013 | 2013-12-31 | $1.09B | $248.0M | +29.31% | +21.40% |
| Q3 2013 | 2013-09-30 | $1.67B | −$566.0M | −25.37% | +35.74% |
| Q2 2013 | 2013-06-30 | $1.92B | $451.0M | +30.74% | +40.88% |
| Q1 2013 | 2013-03-31 | $1.10B | −$333.0M | −23.25% | +25.39% |
| Q4 2012 | 2012-12-31 | $846.0M | — | — | +16.25% |
| Q3 2012 | 2012-09-30 | $2.23B | — | — | +49.49% |
| Q2 2012 | 2012-06-30 | $1.47B | — | — | +32.65% |
| Q1 2012 | 2012-03-31 | $1.43B | — | — | +34.32% |
AbbVie free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $16.79B to $17.82B, a compound annual growth rate of 1.19%. AbbVie's latest reported quarter, Q2 2026, generated $3.11B in free cash flow, a decrease of 36.24% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
